Patient Centricity and Diversity: How to Design for Both in a World of Complex Clinical Trials

Patient diversity and representation in clinical trials have become a priority for stakeholders across the industry and for regulatory authorities around the world. There are many challenges in the recruitment and retention of under-represented populations in clinical trials. How can the research community address the root causes for the lack of diversity, even at the study design concept stage?

With the right strategy, an ongoing commitment to ensuring representation and a collaborative effort between the sponsor, the CRO and investigative sites, representative diversity in trial populations can be achieved. The key to achieving diversity in clinical trial participation is to understand the drivers of diversity in the design of your trial.

Join the featured speakers as they discuss some of the factors underpinning the lack of patient diversity in clinical trials, investigate the implications this has for patients and discuss what we can do to design more patient-centric and diverse clinical trials.

Speakers

Todd Georgieff, Digital Protocol Consultant

Todd Georgieff has been working in drug development for more than 30 years. He has extensive experience in global clinical operations and has also held leadership roles in many large process improvement, technology and organizational change initiatives. In the past few years, Todd has been working on projects relating to the digitization of clinical research, both at Roche and Genentech and in several cross-industry collaborations. These include TransCelerate’s Digital Data Flow initiative, leading the Precision Cancer Consortium Clinical Trial Patient Matching workstream, participating in the Decentralized Trials Research Alliance and several others. Many of these initiatives aim to make drug development more efficient and sustainable and to help our industry “break the document paradigm”.

Message Presenter

Scott Chetham, Co-Founder & CEO, Faro Health Inc.

Scott Chetham, PhD, is an experienced Healthcare Entrepreneur who is currently the CEO and co-founder of Faro Health. Scott leads the strategy for the Faro Health platform, which is designed to power clinical development by connecting data to decision-making in a fundamentally new way. Previously, he was the Head of Clinical Research Operations and Data Management at Verily Life Sciences, formerly known as Google Life Sciences. This multi-faceted strategic and operational role involved leading the clinical strategy, clinical teams, process development and operations for all clinical projects of the company, including Google and Google[x]. Scott has also served as a Venture Partner at Versant Ventures, CTO and Co-founder of Intersection Medical (sold to ImpediMed) and VP of Clinical Affairs (ImpediMed). In these latter two roles, he was responsible for clinical research strategy and operations.

Message Presenter

Angie Maurer, Vice President of Product, Faro Health Inc.

Angie Maurer has over 20+ years of clinical research experience in the pharmaceutical, biotechnology, medical device and diagnostic industries worldwide. Prior to Faro Health, Angie worked with various companies from small start-ups to large companies providing expertise in Quality Risk Management (program and software development), GCP compliance, learning management, process development and improvement, management and oversight of drug/device development programs, clinical trial management and QA clinical audits. Angie is a highly regarded professional with progressive, successful experience in providing clinical quality and compliance solutions with a proven record of developing successful strategies and companies in the healthcare industry.

Message Presenter